retatrutide phase 3 results october 2025 3: 60% Achieved Surgical-Level Weight Loss Retatrutide Timeline: Week-by-Week Results (48

Suitability for any therapyincluding currently approved optionsis determined solely during a comprehensive clinical assessment

Notably, genetically proxied agonists of GIPR, GLP-1R, and GCGR/GLP-1R all showed causal effects on lower levels of BMI, while the GIPR/GLP-1R agonist and GCGR/GIPR/GLP-1R agonist did not provide evidence of decreasing BMI, potentially attributed to the heterogeneity among variants (Table 2)

As such, many patients medications lists can include both oral and injectable hypoglycemics

Proper injection technique is crucial to ensure the medication is administered correctly and to minimize potential injection site reactions